Home
CGON
CGON News

Latest CG ONCOLOGY INC (CGON) News on January 19, 2025

Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect?

Zacks

3 days ago

Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect?

MT Newswires

12 days ago

TD Cowen Initiates CG Oncology at Buy

How to Navigate the Stock and Bond Markets in 2025

The Wall Street Journal

16 days ago

How to Navigate the Stock and Bond Markets in 2025

MT Newswires

a month ago

CG Oncology Insider Sold Shares Worth $19,600,000, According to a Recent SEC Filing

MT Newswires

a month ago

CG Oncology Closes $238 Million Offering

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire

a month ago

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

MT Newswires

a month ago

CG Oncology Prices $204.4 Million Public Offering

CG Oncology Announces Pricing of Public Offering

GlobeNewswire

a month ago

CG Oncology Announces Pricing of Public Offering

MT Newswires

a month ago

CG Oncology Files for Proposed Public Share Offering

CG Oncology Announces Proposed Public Offering

GlobeNewswire

a month ago

CG Oncology Announces Proposed Public Offering

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

GlobeNewswire

a month ago

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology announces data from Phase 3 BOND-003 trial

TipRanks

a month ago

CG Oncology announces data from Phase 3 BOND-003 trial

MT Newswires

a month ago

CG Oncology Reports 74.5% Complete Response in Study of Bladder Cancer Candidate

CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate

Benzinga

a month ago

CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

GlobeNewswire

a month ago

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024

GlobeNewswire

2 months ago

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting

GlobeNewswire

2 months ago

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting

CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

2 months ago

CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

MT Newswires

2 months ago

CG Oncology's Q3 Loss Narrows

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

2 months ago

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

GlobeNewswire

2 months ago

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

MT Newswires

3 months ago

UBS Initiates CG Oncology With Buy Rating, $60 Price Target

We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth

Simply Wall St.

4 months ago

We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth

MT Newswires

4 months ago

RBC Initiates CG Oncology at Outperform, Speculative Risk With $66 Price Target

Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock

Insider Monkey

4 months ago

Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock

MT Newswires

5 months ago

CG Oncology Insider Sold Shares Worth $23,000,089, According to a Recent SEC Filing

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire

5 months ago

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

MT Newswires

5 months ago

Roth MKM Initiates CG Oncology at Buy With $65 Price Target

Bullish CG Oncology Insiders Loaded Up On US$5.06m Of Stock

Simply Wall St.

5 months ago

Bullish CG Oncology Insiders Loaded Up On US$5.06m Of Stock

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

5 months ago

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

Institutional investors in CG Oncology, Inc. (NASDAQ:CGON) must be dismayed after prices dropped by 13% last week

Simply Wall St.

6 months ago

Institutional investors in CG Oncology, Inc. (NASDAQ:CGON) must be dismayed after prices dropped by 13% last week

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

GlobeNewswire

7 months ago

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

GlobeNewswire

7 months ago

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

GlobeNewswire

8 months ago

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

8 months ago

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

GlobeNewswire

9 months ago

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

GlobeNewswire

9 months ago

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

GlobeNewswire

9 months ago

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

GlobeNewswire

10 months ago

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

GlobeNewswire

a year ago

CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

MOD vs. RACE: Which Stock Is the Better Value Option?

Zacks

a year ago

MOD vs. RACE: Which Stock Is the Better Value Option?

Oil: Where prices could be heading after January gains

Yahoo Finance Video

a year ago

Oil: Where prices could be heading after January gains

UMB (UMBF) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks

a year ago

UMB (UMBF) Reports Q4 Earnings: What Key Metrics Have to Say

Analysts Estimate PJT Partners (PJT) to Report a Decline in Earnings: What to Look Out for

Zacks

a year ago

Analysts Estimate PJT Partners (PJT) to Report a Decline in Earnings: What to Look Out for

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Business Wire

a year ago

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Business Wire

a year ago

Form 8.3 - DX (Group) plc

Africa Smart Manufacturing Market Sees Upsurge: Comprehensive Analysis and Growth Forecasts Up to 2030

GlobeNewswire

a year ago

Africa Smart Manufacturing Market Sees Upsurge: Comprehensive Analysis and Growth Forecasts Up to 2030

In Bad News for IPO Market, BrightSpring Closes Below Offering Price

The Wall Street Journal

a year ago

In Bad News for IPO Market, BrightSpring Closes Below Offering Price

Boston Beer and Huntsman have been highlighted as Zacks Bull and Bear of the Day

Zacks

a year ago

Boston Beer and Huntsman have been highlighted as Zacks Bull and Bear of the Day

Tiger Pistol Expands Partnership with The Wendy's Company to Empower Franchisees with TikTok Advertising

PR Newswire

a year ago

Tiger Pistol Expands Partnership with The Wendy's Company to Empower Franchisees with TikTok Advertising

CG Oncology Announces Pricing of Upsized Initial Public Offering

Business Wire

a year ago

CG Oncology Announces Pricing of Upsized Initial Public Offering

Sportradar Announces Additional Strategic Actions to Streamline Organizational Structure and Drive Growth and Innovation

GlobeNewswire

a year ago

Sportradar Announces Additional Strategic Actions to Streamline Organizational Structure and Drive Growth and Innovation

Sensata Technologies Holding's (NYSE:ST) Returns On Capital Not Reflecting Well On The Business

Simply Wall St.

a year ago

Sensata Technologies Holding's (NYSE:ST) Returns On Capital Not Reflecting Well On The Business

3 Wireless Stocks Set to Sail Against the Ailing Industry

Zacks

a year ago

3 Wireless Stocks Set to Sail Against the Ailing Industry

Q3 Earnings Outperformers: Varonis (NASDAQ:VRNS) And The Rest Of The Cybersecurity Stocks

StockStory

a year ago

Q3 Earnings Outperformers: Varonis (NASDAQ:VRNS) And The Rest Of The Cybersecurity Stocks

2024 Will Be the Year of AI. 2 Top Stocks I Expect to Surge.

Motley Fool

a year ago

2024 Will Be the Year of AI. 2 Top Stocks I Expect to Surge.

Q3 Rundown: Freshworks (NASDAQ:FRSH) Vs Other Sales Software Stocks

StockStory

a year ago

Q3 Rundown: Freshworks (NASDAQ:FRSH) Vs Other Sales Software Stocks

Sprinklr Appoints Trac Pham New Interim Chief Operating Officer, Authorizes $100 Million Stock Buyback Program, and Reaffirms Financial Guidance for Q4 and Full Year FY 2024

Business Wire

a year ago

Sprinklr Appoints Trac Pham New Interim Chief Operating Officer, Authorizes $100 Million Stock Buyback Program, and Reaffirms Financial Guidance for Q4 and Full Year FY 2024

Why Asana (ASAN) Stock Might be a Great Pick

Zacks

a year ago

Why Asana (ASAN) Stock Might be a Great Pick

Dycom Industries, Inc.'s (NYSE:DY) 32% Price Boost Is Out Of Tune With Earnings

Simply Wall St.

a year ago

Dycom Industries, Inc.'s (NYSE:DY) 32% Price Boost Is Out Of Tune With Earnings

PR Newswire

a year ago

Autohome Inc. Announces CEO and Board Changes

PR Newswire

a year ago

Autohome Inc. Announces Cash Dividend and Amendment to Dividend Policy

Royce Investment Partners Commentary: Can 2 Small-Cap Aviation Holdings Fly Higher?

GuruFocus.com

a year ago

Royce Investment Partners Commentary: Can 2 Small-Cap Aviation Holdings Fly Higher?

Some BRP Inc. (TSE:DOO) Analysts Just Made A Major Cut To Next Year's Estimates

Simply Wall St.

a year ago

Some BRP Inc. (TSE:DOO) Analysts Just Made A Major Cut To Next Year's Estimates

Be Wary Of Autohome (NYSE:ATHM) And Its Returns On Capital

Simply Wall St.

a year ago

Be Wary Of Autohome (NYSE:ATHM) And Its Returns On Capital

Insiders hold 82% of Summit Therapeutics Inc. (NASDAQ:SMMT), and they've been buying recently

Simply Wall St.

a year ago

Insiders hold 82% of Summit Therapeutics Inc. (NASDAQ:SMMT), and they've been buying recently

LCI Industries (NYSE:LCII) Has Affirmed Its Dividend Of $1.05

Simply Wall St.

a year ago

LCI Industries (NYSE:LCII) Has Affirmed Its Dividend Of $1.05

Analysts' Revenue Estimates For Crescent Point Energy Corp. (TSE:CPG) Are Surging Higher

Simply Wall St.

a year ago

Analysts' Revenue Estimates For Crescent Point Energy Corp. (TSE:CPG) Are Surging Higher

Advanced Energy Industries Declares Dividend

Hart Energy

a year ago

Advanced Energy Industries Declares Dividend

Share on Social Networks: